Oruka Therapeutics (NASDAQ:ORKA) Coverage Initiated at Jefferies Financial Group

Stock analysts at Jefferies Financial Group began coverage on shares of Oruka Therapeutics (NASDAQ:ORKA) in a research report issued to clients and investors on Thursday,Benzinga reports. The firm set a “buy” rating and a $45.00 price target on the stock. Jefferies Financial Group’s price target would indicate a potential upside of 59.01% from the stock’s previous close.

Other equities analysts have also recently issued research reports about the company. Barclays began coverage on Oruka Therapeutics in a report on Monday, October 13th. They set an “overweight” rating and a $48.00 target price for the company. Guggenheim assumed coverage on Oruka Therapeutics in a report on Monday, October 27th. They issued a “buy” rating and a $60.00 price objective on the stock. HC Wainwright dropped their target price on shares of Oruka Therapeutics from $45.00 to $40.00 and set a “buy” rating for the company in a report on Monday, October 27th. BTIG Research reiterated a “buy” rating and issued a $56.00 target price on shares of Oruka Therapeutics in a research report on Monday, September 29th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $45.14.

Oruka Therapeutics Stock Performance

Oruka Therapeutics stock opened at $28.30 on Thursday. The stock has a market capitalization of $1.18 billion, a P/E ratio of -10.07 and a beta of -0.30. The company’s fifty day moving average price is $22.16 and its 200 day moving average price is $16.01. Oruka Therapeutics has a 1 year low of $5.49 and a 1 year high of $29.86.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.01. Sell-side analysts predict that Oruka Therapeutics will post -3.41 EPS for the current year.

Hedge Funds Weigh In On Oruka Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. ADAR1 Capital Management LLC acquired a new stake in Oruka Therapeutics during the first quarter worth $1,362,000. Affinity Asset Advisors LLC grew its holdings in shares of Oruka Therapeutics by 47.9% during the 1st quarter. Affinity Asset Advisors LLC now owns 545,362 shares of the company’s stock worth $5,595,000 after purchasing an additional 176,664 shares during the period. Braidwell LP increased its position in shares of Oruka Therapeutics by 37.0% during the 1st quarter. Braidwell LP now owns 1,572,426 shares of the company’s stock worth $16,133,000 after purchasing an additional 424,750 shares during the last quarter. Aberdeen Group plc purchased a new stake in Oruka Therapeutics in the 2nd quarter valued at about $879,000. Finally, OMERS ADMINISTRATION Corp lifted its position in Oruka Therapeutics by 126.8% in the first quarter. OMERS ADMINISTRATION Corp now owns 44,900 shares of the company’s stock valued at $461,000 after buying an additional 25,100 shares during the last quarter. 56.44% of the stock is currently owned by institutional investors and hedge funds.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.